September 7, 2022
Sysmex said on September 6 that it has filed its gene panel test OncoGuide NCC Oncopanel System for an additional indication for use as a companion diagnostic (CDx) for futibatinib, an FGFR inhibitor being developed by Taiho Pharmaceutical. The submission...read more